Biomoda

Website: http://www.biomoda.com/

Biomoda is a cancer diagnostics company focused on the development of an inexpensive, simple, highly accurate in-vitro test for the early detection of lung cancer. The CyPath® assay is based upon Biomoda’s patent estate centered on molecular marker technology originally developed at the Los Alamos National Laboratory

In recent years, lung cancer has become the leading cause of cancer deaths worldwide with 1.2 million new cases reported annually.  More than 170,000 Americans are diagnosed with the disease each year, and despite research efforts the prognosis is still poor. According to the International Association for the Study of Lung Cancer, in two-thirds of lung cancer patients, the cancer has spread to regional lymph nodes or beyond at the time of initial diagnosis, resulting in a dismal five-year survival rate of only 15%.  Early detection increases the survival rate to approximately 92%, according to an I-ELCAP study published in the New England Journal of Medicine.

The Biomoda technology directly addresses a global health crisis by making the early diagnosis of the deadliest cancers available at an affordable cost to large populations worldwide..